The True Costs of Bringing Cell Therapies to Market

Understanding Cost Drivers and Strategic Trade-Offs Behind CGT Manufacturing and Platform Choices

5

November

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

The promise of widespread access to the cell & gene therapies hinges on the industry’s ability to bring them to market. Even as the patient demand grows, therapy developers today are burdened with increasing cost pressures. Understanding the total cost of ownership (TCO) is now critical to navigating the transition from early development to commercial manufacturing.

In this webinar, experts in the CGT space will explore the financial and operational realities therapy developers face as they transition from preclinical to commercial manufacturing.

What you’ll learn:

  • The hidden costs that often go unaccounted for in early tech decisions
  • How early decisions around process design can shape or strain commercial scale-up
  • Practical trade-offs between automation, flexibility, and platform integration
  • How to evaluate and manage total cost of ownership (TCO) across clinical and commercial stages

 

Whether you’re preparing your first IND or planning for commercial launch, this webinar will help you build a strategy that’s scientifically sound and economically sustainable.

Speakers

Select a speaker to learn more

Back
Thomas Heathman
President, North America

Tom currently serves as the president for Ori Biotech, responsible for commercial launch of Ori’s technology, the IRO Platform, including deployments to initial customer base of Pharma and CDMOs. Prior to this, Tom served as the Business Leader for North America for Minaris Regenerative Medicine, a leading CDMO for the ATMP industry. During his time with Minaris, he led the growth of the North America business including the signing of commercial manufacturing agreements with leading therapy developers. Tom has a PhD in Cell and Gene Therapy Manufacturing from Loughborough University in the UK.

Next speaker
Back
Bruce Thompson
Chief Technology Officer
Bruce Thompson brings more than 25 years of experience to his position as Chief Technology Officer. Bruce is the Founding CEO of Kincell where he built the technical and operations team and launched Kincell’s tech-savvy CDMO offerings in the marketplace. Prior to his role with Kincell, Bruce was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped to build the development and GMP manufacturing capabilities and served as a technical advisor.

Bruce has over 18 years of CMC strategy, product development and cell therapy manufacturing experience. As Vice President of Process Sciences at Lyell Immunopharma, he was responsible for Process and Analytical Development, as well as tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Before Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He supported more than 15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs. Bruce also spent nearly 10 years at Pfizer in the Pharmaceutical Sciences division where he gained expertise in analytical and process development.

Bruce received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University and Ph.D. in Microbiology and Immunology from the University of Louisville.
Next speaker
Back
John Lunger
Chief Patient Supply Officer
John Lunger served as Chief Patient Supply Officer at Adaptimmune and was a member of their executive team. John led the teams responsible for producing and delivering products to patients, accelerating supply execution, and optimizing the supply chain to be ready for commercialization.

Previously, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack’s first commercial product launched in October of 2015. Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he held a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a U.S. Navy submarine followed by strategic consulting with Accenture. He currently serves as a consultant and Technical Advisory Board member of Nkarta, Inc. (Nasdaq: NKTX). He previously served as a non-executive director of Genocea Biosciences, Inc. (Nasdaq: GNCA).

John holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the U.S. Naval Academy and an MBA in economics and operations management from the University of Chicago’s Booth School of Business.
Next speaker
Back
Amy Hay
Chief Business Officer, CTMC

Amy Hay is an experienced leader in setting strategy, negotiating transactions and implementing
global oncology programs. Her expertise lies within identifying synergistic relationships that
provide value and her portfolio has ranged from working with health systems, governments,
corporations, providers and industry leaders worldwide.

In April 2021, Siemens Healthineers acquired Varian and Amy has been leading integration teams within the oncology workstream to ensure synergies across both organizations are identified and targets are exceeded in commercial acceleration and platform expansion.

Today Amy is responsible for the strategic initiatives and the deployment of “Oncology as a Service” (OaaS), which aggregates medical technology, clinical solutions and technology enabled services globally. Set by her strategy, Varian has built out technology enabled solutions that span virtual tumor boards and molecular analytics. Within her first year, she closed a partnership with Ayala Health in the Philippines and CHRISTUS Health in the US, providing cumulative revenues of more than $75M.

Amy joined Varian through the acquisition of her consulting company, Evolve International, in January of 2020. Evolve provided strategic consulting to healthcare providers, not-for-profit organizations, health related startups and big data technology companies such as the Eliminate Cancer Initiative in Australia, M2GEN at the Moffitt Cancer Center, City of Hope, Nano and the Cancer Commons.

Next speaker

Enquiry